{"id":986,"date":"2020-01-09T15:35:18","date_gmt":"2020-01-09T18:35:18","guid":{"rendered":"https:\/\/www.vitapharmaconsulting.com\/en\/?post_type=noticias&p=986"},"modified":"2022-04-27T15:36:35","modified_gmt":"2022-04-27T18:36:35","slug":"anvisa-proposal-for-new-bioavailability-bioequivalence-ba-be-studies","status":"publish","type":"noticias","link":"https:\/\/www.vitapharmaconsulting.com\/en\/news\/2020\/01\/09\/anvisa-proposal-for-new-bioavailability-bioequivalence-ba-be-studies\/","title":{"rendered":"ANVISA – Proposal for new Bioavailability\/ Bioequivalence (BA\/BE) Studies"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

On January 2, 2020 ANVISA published in the Brazil the Public Consultation N\u00ba 760 which provides on criteria for conducting studies of Bioavailability\/Bioequivalence (BA\/ BE).<\/p>\n

The proposal aims to update RE 1170\/2006 about some legal requirements in regulatory convergence with the United States and European countries.<\/p>\n

The Public Consultation is open from today 9th January 2020, and the deadline for contributions is 8th August 2020.<\/p>\n

Count on Vita to conduct your regulatory projects in Europe and Latin America.<\/p>\n

Contact us: info@vitaraconsulting.com<\/a><\/p>\n

\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
<\/div>\n<\/section>\n<\/article>\n